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Abstract
Introduction: Frontotemporal dementia (FTD) is a common cause of early-onset dementia with a significant
genetic component, as underlined by the recent identification of repeat expansions in the gene C9ORF72 as a
major cause of FTD and motor neuron disease. Understanding the neurobiology and clinical phenomenology of
this novel mutation is currently a major research focus. However, few data are available concerning the
longitudinal evolution of this genetic disease. Here we present longitudinal neuropsychological and neuroimaging
data on a cohort of patients with pathological repeat expansions in C9ORF72.
Methods: Following a review of the University College London FTD DNA database, 20 cases were retrospectively
identified with a C9ORF72 expansion. Twelve cases had longitudinal neuropsychology data available and six of
these cases also had longitudinal volumetric brain magnetic resonance imaging. Cortical and subcortical volumes
were extracted using FreeSurfer. Rates of whole brain, hemispheric, cerebellar and ventricular change were
calculated for each subject. Nonlinear fluid registration of follow-up to baseline scan was performed to visualise
longitudinal intra-subject patterns of brain atrophy and ventricular expansion.
Results: Patients had low average verbal and performance IQ at baseline that became impaired (< 5th percentile)
at follow-up. In particular, visual memory, naming and dominant parietal skills all showed deterioration. Mean rates
of whole brain atrophy (1.4%/year) and ventricular expansion (3.2 ml/year) were substantially greater in patients
with the C9ORF72 mutation than in healthy controls; atrophy was symmetrical between the cerebral hemispheres
within the C9ORF72 mutation group. The thalamus and cerebellum showed significant atrophy whereas no cortical
areas were preferentially affected. Longitudinal fluid imaging in individual patients demonstrated heterogeneous
patterns of progressive volume loss; however, ventricular expansion and cerebellar volume loss were consistent
findings.
Conclusion: Disease evolution in C9ORF72-associated FTD is linked neuropsychologically with increasing
involvement of parietal and amnestic functions, and neuroanatomically with rather diffuse and variable cortical and
central atrophy but more consistent involvement of the cerebellum and thalamus. These longitudinal profiles are
consistent with disease spread within a distributed subcortical network and demonstrate the feasibility of
longitudinal biomarkers for tracking the evolution of the C9ORF72 mutation phenotype.
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Introduction
Frontotemporal dementia (FTD) is characterised by early
behavioural change and progressive erosion of social cog-
nition associated with frontotemporal lobar degeneration
[1]. A substantial number of cases of FTD have a familial
basis [2], and an expanded hexanucleotide (GGGGCC)
repeat insertion in a noncoding promoter region of ORF
72 of chromosome 9 (C9ORF72) was recently identified
as an important cause of FTD and motor neuron disease
[3,4]. Recent reports of C9ORF72 mutations suggest
these are a common cause of FTD and motor neuron dis-
ease, representing approximately one-third of all cases
due to genetic mutations [5,6], of comparable frequency
to mutations in progranulin (GRN) and micro-tubule
protein tau (MAPT) as a cause of autosomal dominant
FTD [6].
Clinically, C9ORF72 expansions have been associated
with a behavioural dysexecutive phenotype but also with
notable early features including psychosis and anxiety as
well as impaired episodic memory [6,7]. Individual cross-
sectional magnetic resonance imaging (MRI) has revealed
a highly variable imaging phenotype with involvement of
frontal, temporal and parietal cortices, and limited pre-
vious longitudinal data have suggested similar rates of
whole brain atrophy in C9ORF72 and MAPT mutation
cases [6]. Group-level cross-sectional imaging studies
have confirmed this distributed pattern of atrophy as well
as emphasising additional cerebellar and subcortical
involvement [6,8,9]. Both imaging and clinical studies
suggest that the neurodegenerative process associated
with the C9ORF72 expansion is rather diffuse [10].
Whilst early symptoms are most in keeping with frontal
lobe dysfunction, parietal dysfunction becomes more
apparent as the disease progresses [6]. These clinical fea-
tures suggest that the disease may propagate along a ros-
trocaudal gradient, perhaps spreading via a distributed
brain network. Understanding the clinical and radiologi-
cal evolution of C9ORF72-associated FTD is an impor-
tant issue. Detailed studies of longitudinal imaging
profiles and neuropsychological changes associated with
C9ORF72 mutations remain limited: longitudinal studies
may enable evaluation of candidate biomarkers both for
diagnosis and future clinical trials of disease-modifying
agents. More fundamentally, the concept of network-led
degeneration is gaining currency as an important general
theme in neurodegeneration [11] and C9ORF72-asso-
ciated FTD, as a novel genetic proteinopathy, may offer
fresh insights into the mechanisms of neurodegenerative
disease propagation.
Here we present longitudinal data on a cohort of
patients with FTD associated with C9ORF72 expansions.
We detail profiles of neuropsychological progression,
rates of whole brain, cerebellar and subcortical atrophy
and anatomical profiles of disease progression using
nonlinear fluid registration of serial MRI.
Methods
Case ascertainment
Twenty cases from a previously published DNA cohort
comprising 227 cases within the frontotemporal lobar
degeneration spectrum [6] were found to harbour a
C9ORF72 expansion using the repeat-primed PCR as pre-
viously published [4]. Mutations were called where more
than 30 repeats were shown consistently. For the purpose
of reporting longitudinal change only cases with a mini-
mum of two neuropsychological assessments or volu-
metric MRI scans were included. In total 12 individuals
(mean age 59.4 years (± 6.8 years), seven male) had longi-
tudinal neuropsychological data and six of these cases
(mean age 62.7 years (± 7 years), five male) also had long-
itudinal volumetric MRI scans. All cases identified had
been assessed in the Specialist Cognitive Disorders Clinic
at the National Hospital for Neurology and Neurosurgery
by an experienced cognitive neurologist and all met cur-
rent consensus criteria for a diagnosis of behavioural var-
iant FTD [1]. Two cases had additional clinical features
of motor neuron disease at presentation.
The study was approved by the local research ethics
committee under Declaration of Helsinki guidelines and
all subjects gave informed consent for participation.
Neuropsychological assessment
The mean duration between serial neuropsychological
assessments was 1.4 years (± 0.7 years). General intellec-
tual function was assessed using the Wechsler Adult Intel-
ligence Scale - Revised or the Wechsler Abbreviated Scale
of Intelligence [11,12]. Executive function was assessed
using the Weigl test, the Stroop colour-word test or the
Hayling test [13-15]. Verbal memory and visual memory
were assessed with the Recognition Memory Test for
words and faces respectively [16]. Naming was assessed
using the Graded Naming Test or the Oldfield Naming
Test [17,18]. Visuospatial and visual perception skills were
assessed using subsets of the Visual Object and Spatial
Perception battery [19]. Calculation and spelling were
assessed with the Graded Difficulty Arithmetic test [20]
and the Baxter Spelling tests [21] respectively. Raw scores
were converted into percentiles for reporting.
Brain image acquisition and processing
Serial T1-weighted magnetic resonance volumetric brain
MRI was performed using a Magnetization Prepared
Rapid Gradient Echo sequence: three studies were
acquired on a 1.5T GE Signa scanner (General Electric
Milwaukee, WI, USA) (256 × 256 matrix; 1.5 mm slice
thickness) and three studies acquired on a 3.0T Siemens
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Trio scanner (Siemens, Germany) (256 × 256 matrix; 1.1
mm slice thickness). Patient data were compared with
data from 15 age-matched (mean age 57.7 years; 10
male, five female) healthy controls with two volumetric
MRI scans (12 controls on the 1.5T scanner, three con-
trols on the 3.0T scanner). The mean duration between
scans was 1.0 years (± 0.2 years) for patients and 1.6
years (± 0.8 years) for controls. All images were visually
inspected for alternative pathologies and motion arte-
fact. Whole brain, ventricular and cerebellar segmenta-
tion was performed by an experienced segmentor using
a semi-automated technique using the MIDAS software
package [22]. Scans underwent affine registration to spa-
tially align the repeat scan to baseline. Rates of whole
brain and cerebellar atrophy and ventricular expansion
were calculated using the boundary shift integral (BSI),
utilising the more robust KN-BSI methodology to pro-
vide automatic quantification of volume change[23].
Rates of change are expressed as the percentage loss
from baseline volume and adjusted to an annualised rate
according to the interval. Scans were registered into
standard space for ventricular and hemispheric segmen-
tation. Ventricular regions included the lateral ventricles
and temporal horn of the lateral ventricles but excluded
the third and fourth ventricles. Visualised cerebellar
regions were dissected from the brainstem at mid-pon-
tine level and images underwent further manual editing
in coronal and sagittal planes to remove any remaining
areas of brainstem. Right and left cerebral hemispheric
volumes were calculated by dividing the brain along the
mid-sagittal section. Finally, total intracranial volumes
were calculated by summing grey matter, white matter
and cerebrospinal fluid volumes acquired using the New
Segment toolbox within Statistical Parametric Mapping
8 [24,25].
Cortical and subcortical regional volumes were
obtained from each subject’s baseline and repeat volu-
metric MRI images using FreeSurfer (v5.1) running the
automated longitudinal processing stream [26]. Default
parameters were used with the exception of applying cus-
tom brain masks defined from the whole brain segmenta-
tion step to improve anatomical accuracy. Segmentations
were visually inspected and edited where necessary.
Volumes from 34 cortical regions following the Desikan
atlas [27] and six subcortical regions (thalamus, caudate,
putamen, globus pallidus, amygdala, hippocampus) were
extracted for each subject and time point.
Following affine registration and bias correction of scan
pairs, each scan set underwent cropping using subject-
specific masks to exclude nonbrain regions. Fluid regis-
tration was performed to visualise intra-subject changes
in brain morphology [28]. Briefly this involves nonlinear
warping of each individual’s repeat scan to match their
baseline scan, generating a deformation field for each




Group-level performance is displayed in Figure 1 and
individual data in Table 1. At baseline the mean general
intellectual function, as reflected in verbal IQ and per-
formance IQ, was in the low average range (mean base-
line verbal IQ = 83 (± 14); mean baseline performance
IQ = 83 (± 15)); over the period of follow-up, both ver-
bal IQ and performance IQ became impaired, declining
by an average of 11 points (mean follow-up verbal IQ =
72 (± 19); mean follow-up performance IQ = 71 (± 23)).
Executive function was severely impaired in the majority
of subjects at baseline (7/12 subjects scored < 5th percen-
tile on at least one executive measure) and deficits became
more frequent over the period of follow-up (10/12 < 5th
percentile). Recognition memory was frequently weak at
baseline, with deficits in verbal (7/12 < 5th percentile) and
visual memory (8/12 < 5th percentile); over the period of
follow-up, visual memory deficits became more frequent
(10/12 < 5th percentile). Naming was impaired in one-half
of the patients at baseline (6/12 < 5th percentile); at
follow-up, naming deficits were evident in the majority (8/
12 < 5th percentile).
Dominant parietal skills were assessed in only five
patients longitudinally; however, three had evidence of
dyscalculia and/or dysgraphia at baseline and four
exhibited at least one of these deficits at follow-up.
Visual perceptual functions remained largely stable over
the period of follow-up, only one subject becoming
impaired.
Neuroimaging findings: atrophy rates
Individual and group volumetric data and rates of whole
brain, hemispheric and ventricular change measured
using BSI are displayed in Figure 2 and Table 2. Rates of
whole brain atrophy varied widely between subjects;
these data have been reported previously for five of the
cases in the present series [6]. The most consistent find-
ing (present in 5/6 cases) was an increased rate of ventri-
cular enlargement in patients with a C9ORF72 mutation:
patients had a mean annualised ventricular expansion
rate of 3.2 (± 2.0) ml/year compared with controls at 0.7
ml/year (± 0.6) (P = 0.001), despite substantial individual
variation. Longitudinal cerebellar atrophy was present in
the majority of individual patients (4/6 cases); the mean
annualised rate of cerebellar atrophy in the patients was
also significantly higher (1.0%/year) than in controls
(0.1%/year; P = 0.02). In addition, the mean annualised
rate of whole brain atrophy in the patients as measured
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Figure 1 Group-level longitudinal performance on neuropsychological measures. Verbal IQ (VIQ) and performance IQ (PIQ) reported as raw
scores. For the purpose of standardising across tests and to visualise changes in performance, raw scores were converted to percentiles. Where a
score of 50th to 75th percentile was reported this was converted to the median value (that is, 62.5) for visualisation.
Table 1 Individual neuropsychological data for baseline and follow-up assessments








1 bvFTD 34.5 1 106 113 < 5th 5th to 10th 95th Pass < 5th
4.5 2 110 110 2nd to
10th
N/A > 25th Pass < 5th
2 bvFTD 3 1 87 78 < 5th < 5th < 5th Pass < 5th
4.7 2 81 76 25th < 10th < 1st Pass < 5th




< 5th Pass < 5th
7.7 2 68 71 < 5th 5th to 10th 5th to
10th
Fail < 5th
4 bvFTD 3 1 73 78 < 5th < 5th 5th to
10th
Pass < 5th
4.5 2 NT NT < 5th < 5th < 1st Pass Reduced





14.4 2 101 114 50th to
75th
> 95th > 75th Pass Pass
6 bvFTD 2.75 1 69 69 < 5th < 5th < 5th Pass < 5th
3.75 2 57 67 < 5th < 5th 5th to
10th
Pass < 5th
7 bvFTD 1 1 80 89 < 5th < 5th 75th Pass Borderline
2.8 2 59 63 < 5th < 5th < 5th Pass < 5th
8 FTD-MND 3 1 69 80 < 5th 5th to 10th 5th to
10th
Pass < 5th
4.2 2 67 65 < 5th < 5th 5th to
10th
Pass < 5th
9 bvFTD 2 1 78 76 < 5th < 5th > 5th Pass Borderline
3 2 78 NT < 5th < 5th > 25th Pass < 5th
10 bvFTD 5 1 82 77 Normal < 5th < 5th Pass Pass
6.6 2 55 77 < 5th < 5th < 1st Pass < 5th
11 FTD-MND 1.5 1 84 82 10th 5th to 10th < 5th Pass < 5th
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using KN-BSI (1.4%) was significantly higher than in con-
trols (0.4%; P = 0.04) Mean atrophy rates for the cerebral
hemispheres considered separately were similar for each
hemisphere (left 2.4%/year; right 2.1%/year) and similar
to the whole brain atrophy rate; atrophy in individual
patients was symmetrical between the hemispheres
across the C9ORF72 mutation group (inter-hemispheric
volume ratio 0.99) and did not become more asymmetric
over the follow-up interval.
Neuroimaging findings: cortical and subcortical regions
Detailed data on subcortical volume change are dis-
played in Table 3. Compared with healthy controls, sig-
nificant subcortical volume loss over time was detected
in the C9ORF72 mutation group in the right thalamus
(P = 0.006), left thalamus (P = 0.03) and left globus pal-
lidus (P = 0.04). No significant change over time was
detected in cortical regions when compared with
controls.
Table 1 Individual neuropsychological data for baseline and follow-up assessments (Continued)
2.5 2 77 60 < 5th < 5th 5th to
10th
Pass < 5th
12 bvFTD 3 1 71 75 < 5th < 5th < 5th Pass Pass
3.7 2 71 74 < 5th < 5th N/A Pass Pass
Raw scores are displayed for verbal IQ (VIQ) and performance IQ (PIQ); otherwise results are displayed as percentiles. Pass, > 5th percentile; borderline, 5th to
10th percentile. bvFTD, behavioural variant frontotemporal dementia; FTD-MND, frontotemporal dementia-motor neuron disease; N/A, not available; NT, not
testable; RMT-F, Recognition Memory Test for faces; RMT-W, Recognition Memory Test for words; VOSP, visual object and space perception battery. aTests of
executive function (Weigl test, Stroop colour-word test or Hayling test).
Figure 2 Change in brain volume and ventricular volume. Change in brain volume (upper panel) and ventricular volume (lower panel) for
each subject expressed as a proportion of the total intracranial volume (TIV) and modelled as a function of disease duration.
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Nonlinear fluid registrations
Fluid-based nonrigid registrations in individual patients
(Figure 3) revealed heterogeneous patterns of whole brain
atrophy across subjects. Over the period of follow-up,
most patients showed a diffuse but dorsally directed pat-
tern of cerebral parenchymal loss, with more variable
involvement of the temporal lobe regions; ventricular
expansion and cerebellar volume loss were consistent fea-
tures. A pattern of generalised progressive atrophy was
apparent in Cases 4 to 6; Case 2 had prominent bifrontal
volume loss, particularly implicating orbitofrontal
cortices; and Cases 1 and 3 had more posterior atrophy,
although expansion of the frontal horns of the lateral
ventricles was also prominent in Case 1.
Discussion and Conclusion
We have described longitudinal neuropsychological and
neuroimaging features in a cohort of patients with FTD
due to a C9ORF72 expansion. Considering the mutation
group as a whole, impaired executive function and also
episodic memory were early and prominent neuropsycho-
logical features. Over follow-up intervals of some 18
Table 2 Individual patient and group brain magnetic resonance imaging volumetric data
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 C9ORF72 Controls
Age at first scan 63.0 59.2 65.6 70.6 66.8 50.7 62.7 (7.0) 58.7 (5.8)
Gender (male:female) 5:1 10:5
Disease duration (years) 2.9 4.2 7.6 2.6 18.8 2.7 6.5 (6.3) N/A
Interscan interval (years) 0.9 1.2 1 0.6 1.1 1.1 1.0 (0.2) 1.6 (0.8)
Total intracranial volume (ml) 1,624 1,835 1,854 1,368 1,686 1,465 1,639 (196) 1,610 (144)
Brain volume, baseline (ml) 1,171 1,351 1,290 876 1,232 1,076 1,166 (171) 1,231 (92)
Brain volume, repeat (ml) 1,146 1,344 1,293 842 1,179 1,072 1,146 (179) 1,226 (92)
Volume change (ml) 25 7 -3 34 53 4 20 (22) 5 (17)
Left hemisphere, baseline (ml) 592 675 651 433 623 542 586 (88) 614 (56)
Left hemisphere, repeat (ml) 579 675 653 415 592 538 575 (93) 611 (53)
Right hemisphere, baseline (ml) 589 686 646 451 619 542 589 (84) 612 (60)
Right hemisphere, repeat (ml) 576 681 648 433 595 541 579 (87) 609 (54)
Ventricle volume, baseline (ml) 44.4 38.2 35.0 40.3 27.8 21.8 34.6 (8.4) 21.4 (11.4)
Ventricle volume, repeat (ml) 47.7 39.0 37.9 44.8 29.8 26.2 37.6 (8.3) 22.5 (12.2)
Brain BSI (%/year) 1.1 -0.2 0.5 4.4 1.0 1.6 1.4 (1.6) 0.4 (0.3)
Ventricle expansion (ml/year) 3.6 0.8 2.5 6.2 1.6 4.3 3.2 (2.0) 0.7 (0.6)
Cerebellar BSI (%/year) -0.5 -0.2 0.6 1.9 1.8 2.6 1.0 (1.3) 0.1 (0.5)
Left hemisphere rate (%/year) 2.4 0.1 -0.4 6.9 4.6 0.6 2.4 (2.9) 0.5 (1.3)
Right hemisphere rate (%/year) 2.4 0.6 -0.2 6.2 3.7 0.1 2.1 (2.5) 0.5 (1.0)
Rates of whole brain, hemispheric and ventricular change. Group data show the mean (standard deviation). BSI, boundary-shift integral; C9ORF72, chromosome 9
open reading frame 72; N/A, not applicable.
Table 3 Subcortical volumes in C9ORF72 mutation and healthy control groups
C9ORF72 Control
% per year Atrophy (ml/year) SD % per year Atrophy (ml/year) SD P value
Thalamus Right 3.4 0.16 0.17 -0.2 -0.02 0.08 0.006
Left 2.5 0.23 0.29 -0.3 -0.02 0.09 0.03
Globus pallidus Right 1.7 0.05 0.10 0.0 0.00 0.03 n/s
Left 2.9 0.03 0.14 -1.1 -0.02 0.06 0.04
Caudate Right -2.6 -0.09 0.15 0.3 0.01 0.06 n/s
Left 0.7 0.02 0.07 0.0 0.00 0.13 n/s
Amygdala Right -2.8 -0.04 0.08 0.1 0.00 0.04 n/s
Left 2.1 0.03 0.06 0.6 0.01 0.06 n/s
Hippocampus Right 1.7 0.07 0.08 1.0 0.04 0.06 n/s
Left 1.4 0.05 0.03 0.6 0.03 0.09 n/s
Putamen Right -0.6 -0.03 0.10 0.0 0.00 0.06 n/s
Left -1.2 -0.06 0.13 -0.1 0.00 0.10 n/s
Mean annualised rates of change are expressed as a percentage (%) and as the millilitre (ml) change from baseline. C9ORF72, chromosome 9 open reading frame
72; n/s, not significant p < 0.05; SD, standard deviation.
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months, there was a significant decline in general intellect
and a further decline in visual memory, naming and parie-
tal skills, whereas nondominant parietal (visuoperceptual)
functions remained relatively intact. Mean brain atrophy
and ventricular expansion rates were increased compared
with healthy controls and broadly in line with rates of
Figure 3 Coronal, sagittal and axial magnetic resonance imaging images showing areas of contraction and expansion. Coronal (left),
sagittal (middle) and axial (right) magnetic resonance imaging brain slices showing longitudinal voxel-compression maps in individual patients,
representing areas of contraction (green-blue) and expansion (yellow-red) over time. Sagittal sections are through the right hemisphere. R, right.
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change in previous longitudinal imaging studies of FTD
[29,30], although there was substantial diversity across the
group. Increased rates of ventricular expansion were con-
sistently observed and may be a candidate biomarker of
disease evolution associated with the C9ORF72 mutation.
Cerebellar atrophy was also a relatively prominent feature
in the C9ORF72 mutation group, with an approximately
10-fold increase in mean atrophy rate compared with con-
trols. Notably, no specific cortical region appeared dispro-
portionately affected; however, subcortical structures
including the thalamus and globus pallidus showed mean
rates of atrophy around three times greater than controls.
Unlike certain other genetic variants of FTD, notably GRN
[31], hemispheric atrophy remained largely symmetrical.
In further contrast to previous neuroimaging findings in
association with mutations of GRN (asymmetric fronto-
temporo-parietal atrophy) andMAPT (antero-medial tem-
poral lobe atrophy) [9], individual atrophy profiles in this
C9ORF72 mutation cohort were highly variable (Figure 2)
- some patients showing chiefly frontal volume loss, whilst
others showed relatively more posterior volume loss. Cere-
bellar atrophy was a relatively consistent feature in indivi-
dual cases here, although whether this is truly a signature
of C9ORF72-associated FTD requires substantiation in lar-
ger patient cohorts from different centres.
The evolution of cognitive deficits here suggests a dis-
tributed disease process implicating frontal, temporal and
parietal cortices, particularly in the dominant hemi-
sphere. Degeneration of a distributed subcortical network
might reconcile this neuropsychological profile with the
rather variable and diffuse profiles of brain atrophy
observed here. Degeneration of thalamus, cerebellum and
thalamic and frontal white matter tracts has been identi-
fied previously in cross-sectional imaging studies of
C9ORF72 expansions [6,8,9]. In the present study, we
provide further evidence that the pathophysiological
mechanisms of C9ORF72-associated FTD target subcorti-
cal networks: rates of thalamic and cerebellar atrophy
and ventricular expansion were disproportionately
increased relative to whole brain atrophy rates, consistent
with involvement of subcortical structures and pathways
[32]. The involvement of the globus pallidus observed
here is in line with the development of extrapyramidal
symptoms in a substantial proportion of C9ORF72 cases
in other series [33], although our patients did not mani-
fest clear-cut features of Parkinsonism. The thalamus,
globus pallidus and cerebellum together act as key hubs
coordinating distributed cortico-subcortical circuits and
the cognitive operations they mediate [34,35]. Early
involvement of such hub regions and projections could
facilitate diffusive spread of the molecular pathology
responsible for the brain degeneration associated with
C9ORF72 expansions [36-38] and might be anticipated to
lead to rapid clinical evolution, although the very wide
range of clinical disease durations among individual
patients with a C9ORF72 mutation remains an important
unsolved problem. Both the thalamus and cerebellum
have been previously implicated in cross-sectional neu-
roimaging work in C9ORF72-associated FTD [6]. The
increased prevalence of cerebellar p62 inclusions with
C9ORF72 expansions compared with other pathologically
proven cases of FTD further supports the role of the cer-
ebellum as an important anatomical nidus of C9ORF72-
associated pathology [6,39].
This study has a number of limitations. Case numbers
here were relatively small and individual variation was
substantial; larger (ideally, multicentre) longitudinal stu-
dies are required to establish the true range of cognitive
and neuroimaging features associated with C9ORF72-
associated FTD and to evaluate candidate biomarkers.
The historical nature of the present cohort was a particu-
lar limitation on the systematic analysis of behavioural
deficits; for example, the nature of the naming impair-
ment here remains ill-defined, and this could in principle
reflect primary word retrieval, semantic or mixed deficits.
Inclusion of presymptomatic carriers in future studies
may allow the earliest behavioural and neuroimaging
markers of disease onset to be determined. The specifi-
city of any candidate biomarkers will only be established
by comparisons with other genetic and sporadic forms of
FTD. We argue that future work should particularly tar-
get subcortical (including cerebellar) structures and cog-
nitive functions in the C9ORF72 mutation group,
incorporating neuroimaging modalities that capture
white matter disintegration: although any synthesis must
be preliminary, we interpret the present findings as
further circumstantial evidence that a distributed cortico-
subcortical network is integral to the phenotypic expres-
sion of C9ORF72-associated FTD.
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